130 related articles for article (PubMed ID: 23125391)
1. Plasma fibrinogen is an accurate marker of disease activity in patients with polymyalgia rheumatica.
McCarthy EM; MacMullan PA; Al-Mudhaffer S; Madigan A; Donnelly S; McCarthy CJ; Molloy ES; Kenny D; McCarthy GM
Rheumatology (Oxford); 2013 Mar; 52(3):465-71. PubMed ID: 23125391
[TBL] [Abstract][Full Text] [Related]
2. Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study.
McCarthy EM; MacMullan PA; Al-Mudhaffer S; Madigan A; Donnelly S; McCarthy CJ; Molloy ES; Kenny D; McCarthy GM
J Rheumatol; 2014 May; 41(5):931-7. PubMed ID: 24692520
[TBL] [Abstract][Full Text] [Related]
3. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
Cantini F; Salvarani C; Olivieri I; Macchioni L; Ranzi A; Niccoli L; Padula A; Boiardi L
Semin Arthritis Rheum; 2000 Aug; 30(1):17-24. PubMed ID: 10966209
[TBL] [Abstract][Full Text] [Related]
4. A disease activity score for polymyalgia rheumatica.
Leeb BF; Bird HA
Ann Rheum Dis; 2004 Oct; 63(10):1279-83. PubMed ID: 15361387
[TBL] [Abstract][Full Text] [Related]
5. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
Martinez-Taboada VM; Blanco R; Fito C; Pacheco MJ; Delgado-Rodriguez M; Rodriguez-Valverde V
Semin Arthritis Rheum; 2001 Feb; 30(4):257-71. PubMed ID: 11182026
[TBL] [Abstract][Full Text] [Related]
6. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.
Spoorenberg A; van der Heijde D; de Klerk E; Dougados M; de Vlam K; Mielants H; van der Tempel H; van der Linden S
J Rheumatol; 1999 Apr; 26(4):980-4. PubMed ID: 10229432
[TBL] [Abstract][Full Text] [Related]
7. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.
Salvarani C; Cantini F; Niccoli L; Macchioni P; Consonni D; Bajocchi G; Vinceti M; Catanoso MG; Pulsatelli L; Meliconi R; Boiardi L
Arthritis Rheum; 2005 Feb; 53(1):33-8. PubMed ID: 15696567
[TBL] [Abstract][Full Text] [Related]
8. The use of receiver operating characteristics analysis in determining erythrocyte sedimentation rate and C-reactive protein levels in diagnosing periprosthetic infection prior to revision total hip arthroplasty.
Ghanem E; Antoci V; Pulido L; Joshi A; Hozack W; Parvizi J
Int J Infect Dis; 2009 Nov; 13(6):e444-9. PubMed ID: 19473865
[TBL] [Abstract][Full Text] [Related]
9. Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis. Clinical and laboratory correlations.
Salvarani C; Macchioni P; Boiardi L; Rossi F; Casadei Maldini M; Mancini R; Beltrandi E; Spacca C; Lodi L; Portioli I
J Rheumatol; 1992 Jul; 19(7):1100-6. PubMed ID: 1512765
[TBL] [Abstract][Full Text] [Related]
10. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).
Leeb BF; Bird HA; Nesher G; Andel I; Hueber W; Logar D; Montecucco CM; Rovensky J; Sautner J; Sonnenblick M
Ann Rheum Dis; 2003 Dec; 62(12):1189-94. PubMed ID: 14644857
[TBL] [Abstract][Full Text] [Related]
11. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission.
Leeb BF; Rintelen B; Sautner J; Fassl C; Bird HA
Arthritis Rheum; 2007 Jun; 57(5):810-5. PubMed ID: 17530664
[TBL] [Abstract][Full Text] [Related]
12. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis.
Proven A; Gabriel SE; O'Fallon WM; Hunder GG
J Rheumatol; 1999 Jun; 26(6):1333-7. PubMed ID: 10381052
[TBL] [Abstract][Full Text] [Related]
13. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.
Palard-Novello X; Querellou S; Gouillou M; Saraux A; Marhadour T; Garrigues F; Abgral R; Salaün PY; Devauchelle-Pensec V
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):773-9. PubMed ID: 26753600
[TBL] [Abstract][Full Text] [Related]
14. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable.
Devauchelle-Pensec V; Saraux L; Berthelot JM; De Bandt M; Cornec D; Guellec D; Marhadour T; Jousse-Joulin S; Gouillou M; Saraux A
Rheumatology (Oxford); 2018 Apr; 57(4):666-670. PubMed ID: 29346621
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic difficulties in polymyalgia rheumatica cases with normal erythrocyte sedimentation rate and C-reactive protein values.
Kara M; Alp G; Koç AM
Medicine (Baltimore); 2023 Sep; 102(39):e35385. PubMed ID: 37773830
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios.
Binard A; De Bandt M; Berthelot JM; Saraux A;
Arthritis Rheum; 2007 Apr; 57(3):481-6. PubMed ID: 17394219
[TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study.
Salvarani C; Cantini F; Niccoli L; Catanoso MG; Macchioni P; Pulsatelli L; Padula A; Olivieri I; Boiardi L
J Rheumatol; 2003 Apr; 30(4):760-3. PubMed ID: 12672196
[TBL] [Abstract][Full Text] [Related]
18. [Serum amyloid A as a useful index of disease activity in polymyalgia rheumatica].
Yamane T; Yamauchi H; Abe N; Torio N; Shimada R; Senba T; Imaizumi Y; Nomura T
Ryumachi; 2003 Jun; 43(3):544-8. PubMed ID: 12910963
[TBL] [Abstract][Full Text] [Related]
19. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis.
Dessein PH; Joffe BI; Stanwix AE
J Rheumatol; 2004 Jun; 31(6):1095-7. PubMed ID: 15170920
[TBL] [Abstract][Full Text] [Related]
20. Different C-reactive protein kinetics in post-operative hip-fractured geriatric patients with and without complications.
Beloosesky Y; Grinblat J; Pirotsky A; Weiss A; Hendel D
Gerontology; 2004; 50(4):216-22. PubMed ID: 15258426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
